AEROVATE THERAPEUTICS INC. - COMMON STOCK

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

27 3 2024 09:20:59 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

25 3 2024 16:10:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

06 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

20 11 2023 16:45:16 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights

13 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights

14 8 2023 08:00:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

11 7 2023 17:00:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

01 6 2023 08:00:01 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference

22 5 2023 13:15:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

15 5 2023 16:05:01 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

29 3 2023 16:50:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference

02 3 2023 08:00:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

23 1 2023 08:00:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

17 11 2022 07:45:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Third Quarter 2022 Financial Results

14 11 2022 07:45:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022

18 10 2022 08:00:01 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Announces Second Quarter 2022 Financial Results

15 8 2022 07:50:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

02 6 2022 08:00:02 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

16 5 2022 17:15:00 提供 Nasdaq GlobeNewswire

Aerovate Therapeutics Announces First Quarter 2022 Financial Results

16 5 2022 08:00:02 提供 Nasdaq GlobeNewswire